96 related articles for article (PubMed ID: 15035154)
1. [Serum beta-CTx(beta-CrossLaps)].
Okabe R
Nihon Rinsho; 2004 Feb; 62 Suppl 2():369-72. PubMed ID: 15035154
[No Abstract] [Full Text] [Related]
2. [Biochemical markers for bone turnover: Serum beta-CTX].
Ichimura S; Iwamoto J
Nihon Rinsho; 2007 Nov; 65 Suppl 9():237-44. PubMed ID: 18161112
[No Abstract] [Full Text] [Related]
3. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
4. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
[TBL] [Abstract][Full Text] [Related]
5. Bone loss after cardiac transplantation.
Lindsay R
N Engl J Med; 2004 Feb; 350(8):751-4. PubMed ID: 14973219
[No Abstract] [Full Text] [Related]
6. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Zikan V; Stepan JJ
Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
[TBL] [Abstract][Full Text] [Related]
7. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
[TBL] [Abstract][Full Text] [Related]
8. [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].
Bahlous A; Kalai E; Hadj Salah M; Bouzid K; Zerelli L
Tunis Med; 2006 Nov; 84(11):751-7. PubMed ID: 17294906
[TBL] [Abstract][Full Text] [Related]
9. Study of the level of biochemical bone markers: NMID osteocalcin and bone resorptive marker (beta CTx) in Thai women.
Bunyaratavej N; Kitimanon N; Boonthitikul S
J Med Assoc Thai; 2001 Oct; 84 Suppl 2():S560-5. PubMed ID: 11853281
[TBL] [Abstract][Full Text] [Related]
10. [N-terminal crosslinking telopeptide of type I collagen].
Fukunaga M
Nihon Rinsho; 2004 Dec; 62 Suppl 12():236-9. PubMed ID: 15658308
[No Abstract] [Full Text] [Related]
11. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
12. [Type I collagen crosslinked C-telopeptides].
Hoshino H; Kushida K
Nihon Rinsho; 2004 Feb; 62 Suppl 2():365-8. PubMed ID: 15035153
[No Abstract] [Full Text] [Related]
13. [The clinical use of biological markers of bone turnover in postmenopausal osteoporosis].
Delmas PD
Ann Biol Clin (Paris); 2001; 59(3):299-308. PubMed ID: 11397679
[No Abstract] [Full Text] [Related]
14. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
15. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
[TBL] [Abstract][Full Text] [Related]
16. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
17. [Effect of alendronate therapy on bone turnover--results of a multicenter study].
Payer J; Killinger Z; Masaryk P; Tomková S; Kmecová Z; Ondrejková J; Necas L; Smoterová J; Ondrejka P; Kratochvilová H
Vnitr Lek; 2000 Oct; 46(10):689-92. PubMed ID: 11344627
[TBL] [Abstract][Full Text] [Related]
18. Postmenopausal osteoporosis and alendronate.
Pérez-López FR
Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
[TBL] [Abstract][Full Text] [Related]
19. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
20. The latest from the ivd industry: prevention, diagnosis and therapy of osteoporosis.
Clin Lab; 2005; 51(1-2):59-61. PubMed ID: 15719707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
